- Jablonska S, Blaszyk M. Scleromyositis (scleroderma/polimyositis overlap) is an entity. J Eur Acad Dermatol Venereol. 2004;18(3):265–266. doi:https://doi.org/10.1111/j.1468-3083.2004.00869.x.
- Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol. 1985;12(6):1140–1148.
- Drake LA, Dinehart SM, Farmer ER, et al; American Academy of Dermatology. Guidelines of care for dermatomyositis. J Am Acad Dermatol. 1996;34(5 Pt 1):824–829.
- Bowyer SL, Lamothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol. 1985;76(2):234–242. doi:https://doi.org/10.1016/0091-6749(85)90708-0.
- Wollenhaupt J, Silverfield J, Lee E, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837–852. doi:https://doi.org/10.3899/jrheum.130683.
- Alunno A, Padjen I, Fanouriakis A, Boumpas D. Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells. 2019;8(8):898. doi:https://doi.org/10.3390/cells8080898.
- Kahn J, Deverapalli S, Rosmarin D. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol. 2018;57(8):1007–1014. doi:https://doi.org/10.1111/ijd.14064.
- You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–1443. doi:https://doi.org/10.1136/annrheumdis-2019-215455.
- Moghadam-Kia S, Charlton D, Aggarwal R, Oddis C. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford). 2019;58(6):1011–1015. doi:https://doi.org/10.1093/rheumatology/key366.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 34, 2021 - Issue 1
Case Studies
Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Preston Williamsa College of Medicine, Texas A&M Health Science Center, Dallas, TexasCorrespondence[email protected]
https://orcid.org/0000-0002-4998-6750
, BAhttps://orcid.org/0000-0002-4998-6750 & Benjamin McKinneyb Department of Family Medicine, Baylor University Medical Center, Dallas, Texashttps://orcid.org/0000-0002-2918-4785
, MDhttps://orcid.org/0000-0002-2918-4785